<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">Cardiovascular morbidity</z:e> and mortality is a major and still unresolved threat to patients with <z:mp ids='MP_0005293'>reduced glucose tolerance</z:mp> and Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In epidemiological studies, in non-diabetic subjects, post-prandial glycaemia is positively associated with the risk of <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and cardiovascular events </plain></SENT>
<SENT sid="2" pm="."><plain>If this epidemiological association is causal, <z:chebi fb="0" ids="2376">Acarbose</z:chebi>, which reduces post-prandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations, should result in a decrease in the risk of these events </plain></SENT>
<SENT sid="3" pm="."><plain>The STOP-<z:mp ids='MP_0002057'>NIDDM</z:mp> trial investigated whether <z:chebi fb="0" ids="2376">Acarbose</z:chebi> reduces the risk of <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and cardiovascular events </plain></SENT>
<SENT sid="4" pm="."><plain>Consequently, the validity of the results of this trial is of major importance for future treatment in non-diabetic and diabetic patients </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: We searched various databases and the Internet for publications of the design and the results of the STOP-<z:mp ids='MP_0002057'>NIDDM</z:mp> trial </plain></SENT>
<SENT sid="6" pm="."><plain>A systematic review of these publications was done with respect to information about potential sources of bias and contradictory information in the articles </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: We found several serious flaws in the STOP-<z:mp ids='MP_0002057'>NIDDM</z:mp> study, especially selection bias, inadequate blinding, bias in data analysis and reporting, and potential sponsoring bias </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The validity of the results of the STOP-<z:mp ids='MP_0002057'>NIDDM</z:mp> trial is seriously flawed </plain></SENT>
<SENT sid="9" pm="."><plain>The clinical benefit of <z:chebi fb="0" ids="2376">Acarbose</z:chebi> and of the reduction of post-prandial glycaemia is unproven </plain></SENT>
</text></document>